Search Results 631-640 of 16744 for GLP-1 agonists
A Study To Confirm the Effectiveness and Safety of Terlipressin in Adults with Hepatorenal Syndrome Type 1 ... 1. Participation eligibility. Participant ...
This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns ...
JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. Study IDs. Site IRB.
... Agonist Therapy. Rochester, Minn ... agonists (DA), to determine the predictors of ICD ... Go to page 11 · Go to page 22 · Go to page 33 · Go to ...
Eligibility last updated 1/08/2025. Questions regarding updates should be directed to the study team contact. Participating Mayo Clinic locations. Study ...
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when ...
Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, ...
Anti-seizure drugs designed to treat epilepsy often are used to control nerve pain associated with diabetes, shingles, and other types of nerve damage.
The purpose of this study is to confirm the effectiveness and safety of terlipressin in the treatment of adult patients with hepatorenal syndrome (HRS) type 1.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!